tert-butyl (1R,5S,6s)-6-formyl-3-azabicyclo[3.1.0]hexane-3-carboxylate | 1246025-64-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl (1R,5S,6s)-6-formyl-3-azabicyclo[3.1.0]hexane-3-carboxylate
• 英文别名: (1R,5S,6s)-tert-butyl 6-formyl-3-azabicyclo[3.1.0]hexane-3-carboxylate；tert-butyl (1R,5S,6r)-6-formyl-3-azabicyclo[3.1.0]hexane-3-carboxylate
• CAS: 1246025-64-8
• 化学式: C₁₁H₁₇NO₃
• 分子量: 211.261
• InChiKey: NZZFUILVSGRYMR-AYMMMOKOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15.0
• 可旋转键数：
  1.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  46.61
• 氢给体数：
  0.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  tert-butyl (1R,5S,6s)-6-formyl-3-azabicyclo[3.1.0]hexane-3-carboxylate 在 正丁基锂 、 戴斯-马丁氧化剂 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 5.5h， 生成 (1R,5S,6r)-3-azabicyclo[3.1.0]hex-6-yl(4-methyl-2-thienyl)methanone
  参考文献：
  名称：

  TW2023/25706

  摘要：

  公开号：
• 作为产物：
  描述：

  (1R,5S,6s)-tert-butyl 6-(hydroxymethyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate 在 戴斯-马丁氧化剂 作用下， 以 二氯甲烷 为溶剂， 以90%的产率得到tert-butyl (1R,5S,6s)-6-formyl-3-azabicyclo[3.1.0]hexane-3-carboxylate
  参考文献：
  名称：

  Synthesis and structure–activity relationship of N-(3-azabicyclo[3.1.0]hex-6-ylmethyl)-5-(2-pyridinyl)-1,3-thiazol-2-amines derivatives as NPY Y5 antagonists

  摘要：

  A novel class of small molecule NPY Y5 antagonists based around an azabicyclo[3.1.0]hexane scaffold was identified through modi. cation of a screening hit. Structure-activity relationships and efforts undertaken to achieve a favourable pharmacokinetic pro. le in rat are described. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.06.140

文献信息

• [EN] COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF<br/>[FR] COMPOSÉ PRÉSENTANT UNE ACTIVITÉ INHIBITRICE DE KDM5 ET UTILISATION PHARMACEUTIQUE ASSOCIÉE
  申请人：ONO PHARMACEUTICAL CO

  公开号：WO2021010492A1

  公开（公告）日：2021-01-21

  The present invention provides KDM5 inhibitor. The compound disclosed herein represented by the general formula (Z): wherein all symbols have the same meanings as the definitions described in the specification; or a salt thereof is useful as a prophylactic and/or therapeutic agent for cancer, Huntington's disease, or Alzheimer's disease and the like.

  本发明提供了KDM5抑制剂。本文所披露的化合物由一般式（Z）表示：其中所有符号的含义与规范中描述的定义相同；或其盐可用作癌症、亨廷顿病或阿尔茨海默病等的预防和/或治疗剂。
• Discovery of Pyrido[2,3-d]pyrimidin-7-one Derivatives as Highly Potent and Efficacious Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Inhibitors for Cancer Treatment
  作者：Yaoliang Sun、Manman Chen、Yuyan Han、Weiqiang Li、Xiaoyu Ma、Zihan Shi、Yang Zhou、Lan Xu、Lei Yu、Yuxiang Wang、Jinghua Yu、Xingxing Diao、Linghua Meng、Shilin Xu

  DOI：10.1021/acs.jmedchem.3c02288

  日期：2024.3.14

  Despite progress in the discovery of ENPP1 inhibitors, the diversity in chemical structures and the efficacy of the agents are far from desirable, emphasizing the demand for novel inhibitors. Herein, we describe the design, synthesis, and biological evaluation of a series of ENPP1 inhibitors based on the pyrido[2,3-d]pyrimidin-7-one scaffold. Optimization efforts led to compound 31 with significant potency

  外核苷酸焦磷酸酶/磷酸二酯酶 1 (ENPP1) 是一种胞外酶，负责水解环单磷酸鸟苷-单磷酸腺苷 (cGAMP)，而环磷酸鸟苷是干扰素基因刺激剂 (STING) 途径的内源性激动剂。抑制 ENPP1 可以触发 STING 并促进抗肿瘤免疫，为癌症免疫治疗提供了一个有吸引力的治疗靶点。尽管 ENPP1 抑制剂的发现取得了进展，但化学结构的多样性和药物的功效远未达到预期，这凸显了对新型抑制剂的需求。在此，我们描述了一系列基于吡啶并[2,3- d ]pyrimidin-7-one支架的ENPP1抑制剂的设计、合成和生物学评价。通过优化工作，化合物31在体外抑制 ENPP1 和刺激 STING 通路方面均具有显着功效。值得注意的是， 31在同基因 4T1 小鼠三阴性乳腺癌模型中证明了体内功效。这些发现为癌症免疫疗法的进一步药物开发提供了一种有前途的先导化合物和新型支架。
• WO2020068867A5
  申请人：——

  公开号：WO2020068867A5

  公开（公告）日：2022-10-03
• [EN] TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS<br/>[FR] AGENTS DE DÉGRADATION BIFONCTIONNELS DE QUINOLONE-BCL6 TRICYCLIQUES
  申请人：[en]TREELINE BIOSCIENCES, INC.

  公开号：WO2023240038A1

  公开（公告）日：2023-12-14

  This disclosure provides compounds of Formula (I) (e.g., Formula (I-aa) (e.g., Formula (I-aa-1), (I-aa-2), (I-aa-3), (I-aa-4), (I-aa-5), or (I-aa-6)), Formula (I-a) (e.g., Formula (I-a-1), (I-a-2), (I-a-3), (I-a-4), (I-a-5), or (I-a-6)), Formula (I-bb) (e.g., Formula (I-bb-1) or (I-bb-2)), or Formula (I-b) (e.g., Formula (I-b-1) or (I-b-2))) or Formula (II), or a pharmaceutically acceptable salt thereof, that induce degradation of a BCL6 protein. These compounds are useful, for example, for treating a cancer in a subject (e.g., a human). This disclosure also provides compositions containing the compounds provided herein as well as methods of using and making the same.
• BRM Targeting Compounds And Associated Methods Of Use
  申请人：Prelude Therapeutics Incorporated

  公开号：US20230365576A1

  公开（公告）日：2023-11-16

  The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.